

해외 바이오의약품 임상 현황 (2021.3.22~2021.3.28)

한국바이오의약품협회, 2021.3.30.
출처: ClinicalTrials.gov

○ 미국 10건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04685499	Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease	Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease	Drug: OBP-301 Drug: Pembrolizumab	Weill Medical College of Cornell University Oncolys BioPharma Inc	Phase 2	---
NCT04579523	²¹² At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	Plasma Cell Myeloma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1	---
NCT04174560	Phase 1 Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	---
NCT04761198	A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.	Solid Tumor, Adult Advanced Solid Tumor Metastatic Solid Tumor	Drug: Etigilimab dosing Drug: Nivolumab	Mereo BioPharma CON Clinical Research	Phase 1 Phase 2	---
NCT04677777	Safety Study of PP-007 in Subjects With Acute Ischemic Stroke	Acute Ischemic Stroke	Biological: PP-007 Other: Standard of care	Prolong Pharmaceuticals	Phase 1	---
NCT04083170	Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers	Acute Erythroid Leukemia Acute Lymphoblastic Leukemia Acute Megakaryoblastic Leukemia Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hematopoietic and Lymphoid Cell Neoplasm HIV Infection Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts Non-Hodgkin Lymphoma Refractory Anemia	Drug: Fludarabine Drug: Cyclophosphamide Drug: Thiotepa Radiation: Total-Body Irradiation Procedure: Umbilical Cord Blood Transplantation Other: Cellular Therapy	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	---
NCT04811664	A Study of SARS CoV-2 Infection and Potential Transmission in University Students Immunized With Moderna COVID-19 Vaccine	SARS-CoV-2 Infection	Biological: Moderna COVID-19 Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	---
NCT04795531	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Placebo insulin icodec Drug: Insulin degludec Drug: Placebo insulin degludec	Novo Nordisk A/S	Phase 3	---
NCT04791319	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis	Dermatitis, Atopic	Drug: Placebo Drug: Bermekimab Drug: Dupilumab	Janssen Research & Development, LLC	Phase 2	---
NCT04740970	A Study of JNJ-64304500 in Participants With Alopecia Areata	Alopecia Areata	Drug: JNJ-64304500 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	---

○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04795531	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Placebo insulin icodec Drug: Insulin degludec Drug: Placebo insulin degludec	Novo Nordisk A/S	Phase 3	---
NCT04791319	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis	Dermatitis, Atopic	Drug: Placebo Drug: Bermekimab Drug: Dupilumab	Janssen Research & Development, LLC	Phase 2	---
NCT04740970	A Study of JNJ-64304500 in Participants With Alopecia Areata	Alopecia Areata	Drug: JNJ-64304500 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	---

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04816890	A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)	Type 1 Diabetes Mellitus	Drug: M1 Pram P037 Drug: Insulin lispro	Adocia	Phase 2	---
NCT04791319	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis	Dermatitis, Atopic	Drug: Placebo Drug: Bermekimab Drug: Dupilumab	Janssen Research & Development, LLC	Phase 2	---

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04813562	Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)	COVID-19	Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56	Jiangsu Province Centers for Disease Control and Prevention Academy of Military Medical Sciences, Academy of Military Sciences, PLA ZHONGYANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd	Phase 2	---
NCT04805736	Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer	Breast Cancer	Procedure: Microwave Ablation Drug: Camrelizumab Procedure: Breast Surgery	The First Affiliated Hospital with Nanjing Medical University Jiangsu HengRui Medicine Co., Ltd.	Phase 2	---
NCT04756648	Phase 1 Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma	Advanced Hepatocellular Carcinoma	Drug: CT0180 Cells	Zhejiang University Carsgen Therapeutics, Ltd.	Phase 1	---
NCT04795531	A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Placebo insulin icodec Drug: Insulin degludec Drug: Placebo insulin degludec	Novo Nordisk A/S	Phase 3	---

○ 일본 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04721977	A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)	Breast Cancer	Drug: Tucatinib Biological: Trastuzumab Drug: Capecitabine	Merck Sharp & Dohme Corp.	Phase 2	---
NCT04738942	A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease	Ulcerative Colitis Crohn's Disease	Drug: Vedolizumab	Takeda	Phase 3	---
NCT04740970	A Study of JNJ-64304500 in Participants With Alopecia Areata	Alopecia Areata	Drug: JNJ-64304500 Drug: Placebo	Janssen Research & Development, LLC	Phase 2	---
NCT04791319	A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis	Dermatitis, Atopic	Drug: Placebo Drug: Bermekimab Drug: Dupilumab	Janssen Research & Development, LLC	Phase 2	---